We searched the electronic databases of PubMed/MEDLINE, EMBASE and Cochrane Library systematically (updated on December 10, 2020) with the search strategies given in Supplementary Table 2; without language and time restriction in any of these databases. Furthermore, references of retrieved studies were searched for eligible studies. Electronic archives of medical societies (Endocrine Society (https://www.endocrine.org/meetings/endo-annual-meetings; accessed December 18, 2020) and Deutsche Gesellschaft für Nuklearmedizin e.V. (https://www.nuklearmedizin.de/jahrestagungen/abstr_online2020/abstract_search.php?navId=227; accessed December 18, 2020) were also searched. Studies meeting the following inclusion criteria were included: routine calcitonin measurement in serum (with or without a pentagastrin or calcium stimulation test) was performed routinely in all included patients with nodular thyroid disease, diagnosed by palpation or ultrasonography. Exclusion criteria were: data for 2 × 2 table not provided; preoperative measurement of calcitonin in serum; calcitonin measurement as screening test, as screening is epidemiologically defined as testing in healthy people (people with thyroid nodules are not healthy); inclusion of patients with familial history of medullary thyroid carcinoma (MTC); incomplete surgery (e.g. lobectomy); case reports or case series; case–control study; duplication of a study (in case of duplication, inclusion of the study with the longest follow-up); only meeting communication, not published as full-text article.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Tips for asking effective questions
+ Description
Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.